secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2026-06-01T11:00:19+00:00
Accession:  0001193125-26-249692
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.02, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors
--------------------------------------------------------------------------------

- Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
- Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.
- Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.
- Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.
- Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer